Low-Risk Organ-Confined Prostate Cancer

CyberKnife monotherapy produced an early and stable reduction in PSA in a patient with low-risk organ-confined prostate cancer with minimal acute urinary toxicities and no noted chronic toxicities.

 

This section provides CyberKnife and TomoTherapy case studies, created by Accuray in collaboration with our centers, showcasing positive outcomes. Individual treatment results may vary. Please consult a physician to discuss individual cases, including eligibility for treatment with Accuray devices.

This section also provides a selected list of publications supporting the use and efficacy of the CyberKnife and TomoTherapy Systems and is not inclusive of all available publications.

For access to a more comprehensive listing of publications related to CyberKnife and TomoTherapy Systems, visit www.pubmed.com.